Cardiac Science Announces Third Quart...(------ ----- Investing Activities:...),Health

Date:11/9/2009

------ ----- Investing Activities: Purchases of short-term investments - (845) Purchases of machinery and equipment (1,034) (983) Proceeds from repayment of note 27 38 Purchases of intangibles (370) - Cash paid for acquisitions - (156) --- ---- Net cash used in investing activities (1,377) (1,946) ------ ------ Financing Activities: Proceeds from exercise of stock options and issuance of shares under employee stock purchase plan 161 541 Minimum tax withholding on restricted stock awards (13) (87) --- --- Net cash provided by financing activities 148 454 --- --- Effect of exchange rate changes on cash and cash equivalents 74 - Net change in cash and cash equivalents (6,240) 4,874 Cash and cash equivalents, beginning of period 37,868 27,721 ------ ------ Cash and cash equivalents, end of period $31,628 $32,595 ======= ======= Cardiac Science Corporation and Subsidiaries Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands) Nine Months Ended September 30, ------------- 2009
'/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery